Information collection activity	Number of respondents	Responses per respondent	Average burden/re- sponse (hours)*
Section I	350	1	0.25 (15 mins).
Section II	350	1	0.50 (30 mins).
Section III	350	4	0.25 (15 mins).
Contract	350	1	0.34 (20 mins).
Affidavit	350	1	0.17 (10 mins).
Lender Cert	1400	1	0.25 (15 mins).

*Burden estimate is based on feedback from applicants or lenders who have completed these forms over the past year.

To request more information on any of the proposed information collection activities or to obtain a copy of the collection of information form(s) and/or instructions, you may call the IHS Reports Clearance Officer on (301) 443-0461. This is not a toll free number. Please send your written comments regarding any or all of the proposed information collection activities to Mr. Lance Hodahkwen, Sr., IHS Reports Clearance Officer, 12300 Twinbrook Parkway, Suite 450, Rockville, MD 20857. Comments may also be sent via facsimile to: (301) 443–1522, or Internet: Lhodahkwen@ihs.ssw.dhhs.gov. Written comments should be received within 60 days of this notice.

Dated: April 16, 1996, Michael H. Trujillo, *Assistant Surgeon General, Director.* [FR Doc. 96–9871 Filed 4–22–96; 8:45 am] BILLING CODE 4160–16–M

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

Name of SEP: Growth and Differentiation of Smooth Muscle Cells.

Date: May 22-23, 1996.

Time: 8:30 p.m.

Place: Holiday Inn Bethesda, 8120

Wisconsin Avenue, Bethesda, Maryland.

Contact Person: Louis M. Ouellette, Ph.D., Two Rockledge Center, Room 7216, 6701 Rockledge Drive, Bethesda, MD 20892–7924 (301) 435–0310.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: April 17, 1996. Susan K. Feldman, *Committee Management Officer, NIH.* [FR Doc. 96–9952 Filed 4–22–96; 8:45 am] BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Meetings

Pursuant to Public Law 92–463, notice is hereby given of the meetings of the following Heart, Lung, and Blood Special Emphasis Panels.

These meetings will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

Name of Panel: Cardiovascular Disease Community Surveillance.

Dates of Meeting: May 7, 1996.

Time of Meeting: 8:00 a.m. *Place of Meeting:* Two Rockledge Center, Room 7111 6701 Rockledge Drive, Bethesda, MD.

Agenda: To provide concept review for cardiovascular disease community surveillance.

Contact Person: Lawton S. Cooper, M.D., M.P.H., NIH/NHLBI/DECA, Rockledge Center Two, Room 8166, 6701 Rockledge Drive, Bethesda, Maryland 20892–7934, (301) 435– 0444.

Name of Panel: Heart Failure Research. Dates of Meeting: May 20, 1996. Time of Meeting: 8:00 a.m.

Place of Meeting: Two Rockledge Center, Conference Room 9B1 6701 Rockledge Drive, Bethesda, MD.

Agenda: Prioritize needs and future directions for research to advance understanding, prevention, and treatment of heart failure.

Contact Person: Leslie Reinlib, Ph.D., NIH/ NHLBI/DHVD, Rockledge Center Two, Rm. 9188, 6701 Rockledge Drive, Bethesda, Maryland 20892–7940, (301) 435–0504. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institute of Health)

Dated: April 17, 1996.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 96–9954 Filed 4–22–96; 8:45 am] BILLING CODE 4140–01–M

National Institute of Dental Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Dental Research Special Emphasis Panel (SEP) meetings:

Name of SEP: National Institute of Dental Research Special Emphasis Panel-Review of RO3 grants 96–22.

Dates: May 16, 1996.

Time: 12:00 pm.

Place: Natcher Building, Rm. 4AN–44F, National Institutes of Health, Bethesda, MD 20892. (teleconference).

Contact person: Dr. George Hausch, Chief, Grants Review Section, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

Name of SEP: National Institute of Dental Research Special Emphasis Panel-Review of RO3 grants 96–23.

Dates: May 17, 1996.

Time: 3:00 pm.

Place: Natcher Building, Rm. 4AN–44F, National Institutes of Health, Bethesda, MD 20892, (teleconference).

Contact person: Dr. George Hausch, Chief, Grants Review Section, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure